Management of Bleeding and Thrombosis in Critically Ill Patients with Liver Disease

Abstract

Bleeding frequently complicates end-stage chronic liver disease, and may follow procedures which are required for effective care of patients with liver failure. Thrombosis is increasingly recognized as common, important, and potentially preventable. Standard laboratory tests may not be useful in predicting bleeding or thrombotic risk or guiding therapy, and functional testing serves a more useful role. A state of rebalanced hemostasis exists in many patients, with hypocoagulability present only in a minority. Approaches to management are poorly supported by high-quality evidence; in this review, a practical pragmatic approach to care and minimization of procedure-related risk is discussed. General measures include the correction of systemic factors that may affect coagulation status, prevention and treatment of infection, and individualized coagulation support therapies for specific clinical situations and procedures.

Keywords

bleeding - thrombosis - liver failure - procedures - coagulation support

• References

• 1 Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 26 (5) 388-393
• 2 Terjung B, Lemnitzer I, Dumoulin FL , et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003; 67 (3) 138-145
• 3 McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99 (5) 1396-1400
• 4 Grabau CM, Crago SF, Hoff LK , et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004; 40 (2) 484-488
• 5 Segal JB, Dzik WH ; Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45 (9) 1413-1425
• 6 Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J ThrombHaemost 2010; 8 (9) 1994-2000
• 7 Habib M, Roberts LN, Patel RK, Wendon J, Bernal W, Arya R. Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation. Liver Int 2014; 34 (5) 672-678
• 8 Lisman T, Bakhtiari K, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J ThrombHaemost 2012; 10 (7) 1312-1319
• 9 Tripodi A, Salerno F, Chantarangkul V , et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41 (3) 553-558
• 10 Agarwal B, Wright G, Gatt A , et al. Evaluation of coagulation abnormalities in acute liver failure. J Hepatol 2012; 57 (4) 780-786
• 11 Kleinegris MC, Bos MH, Roest M , et al. Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. J ThrombHaemost 2014; 12 (10) 1647-1657
• 12 Stravitz RT, Lisman T, Luketic VA , et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012; 56 (1) 129-136
• 13 Tripodi A, Primignani M, Chantarangkul V , et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44 (2) 440-445
• 14 Tripodi A, Primignani M, Chantarangkul V , et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009; 124 (1) 132-136
• 15 Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology 2013; 58 (2) 752-761
• 16 Lisman T, Bongers TN, Adelmeijer J , et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44 (1) 53-61
• 17 Health Technology Assessment Report 11: The clinical and cost effectiveness of thromboelastography/ thromboelastometry (2008). Glasgow: NHS Quality Improvement Scotland. Available at: http://www.healthcareimprovementscotland.org/previous_resources/hta_report/hta_11.aspx . Accessed April 2015
• 18 Chau TN, Chan YW, Patch D, Tokunaga S, Greenslade L, Burroughs AK. Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 1998; 43 (2) 267-271
• 19 Papatheodoridis GV, Patch D, Webster GJ, Brooker J, Barnes E, Burroughs AK. Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography. Hepatology 1999; 29 (4) 1085-1090
• 20 Pereira SP, Rowbotham D, Fitt S, Shearer MJ, Wendon J, Williams R. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol 2005; 42 (3) 365-370
• 21 Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology 2012; 55 (3) 965-967
• 22 O'Shaughnessy DF, Atterbury C, Bolton Maggs P , et al; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126 (1) 11-28
• 23 NICE. Acute upper gastrointestinal bleeding: management. Available at: https://www.nice.org.uk/guidance/cg141 . Published June 2012. Accessed April 2015.
• 24 Giannini EG, Stravitz RT, Caldwell SH. Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis. Hepatology 2014; 60 (4) 1442
• 25 Keeling D, Baglin T, Tait C , et al; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011; 154 (3) 311-324
• 26 Lorenz R, Kienast J, Otto U , et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J GastroenterolHepatol 2003; 15 (1) 15-20
• 27 British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122 (1) 10-23
• 28 Franchini M, Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus 2012; 10 (1) 23-27
• 29 Stinger HK, Spinella PC, Perkins JG , et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008; 64 (2, Suppl): S79-S85 , discussion S85
• 30 Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfus Med 2008; 18 (3) 151-157
• 31 Danés AF, Cuenca LG, Bueno SR, MendarteBarrenechea L, Ronsano JB. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang 2008; 94 (3) 221-226
• 32 Kirchner C, Dirkmann D, Treckmann JW , et al. Coagulation management with factor concentrates in liver transplantation: a single-center experience. Transfusion 2014; 54 (10 Pt 2) 2760-2768
• 33 Fisher NC, Mutimer DJ. Central venous cannulation in patients with liver disease and coagulopathy—a prospective audit. Intensive Care Med 1999; 25 (5) 481-485
• 34 Mumtaz H, Williams V, Hauer-Jensen M , et al. Central venous catheter placement in patients with disorders of hemostasis. Am J Surg 2000; 180 (6) 503-505 , discussion 506
• 35 Tercan F, Ozkan U, Oguzkurt L. US-guided placement of central vein catheters in patients with disorders of hemostasis. Eur J Radiol 2008; 65 (2) 253-256
• 36 Rupp SM, Apfelbaum JL, Blitt C , et al; American Society of Anesthesiologists Task Force on Central Venous Access. Practice guidelines for central venous access: a report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology 2012; 116 (3) 539-573
• 37 Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment PharmacolTher 2005; 21 (5) 525-529
• 38 McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31 (2) 164-171
• 39 De Gottardi A, Thévenot T, Spahr L , et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. ClinGastroenterolHepatol 2009; 7 (8) 906-909
• 40 European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53 (3) 397-417
• 41 Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2 (2) 165-173
• 42 Seeff LB, Everson GT, Morgan TR , et al; HALT–C Trial Group. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. ClinGastroenterolHepatol 2010; 8 (10) 877-883
• 43 Zakaria N, Knisely A, Portmann B , et al. Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy. Blood 2003; 101 (1) 101-103
• 44 Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD ; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49 (3) 1017-1044
• 45 Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36 (3) 437-441
• 46 Caldwell S, Northup PG. Bleeding complication with liver biopsy: is it predictable?. ClinGastroenterolHepatol 2010; 8 (10) 826-829
• 47 Grant A, Neuberger J ; British Society of Gastroenterology. Guidelines on the use of liver biopsy in clinical practice. Gut 1999; 45 (Suppl. 04) IV1-IV11
• 48 Bernal W, Hyyrylainen A, Gera A , et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol 2013; 59 (1) 74-80
• 49 Karvellas CJ, Fix OK, Battenhouse H, Durkalski V, Sanders C, Lee WM ; U S Acute Liver Failure Study Group. Outcomes and complications of intracranial pressure monitoring in acute liver failure: a retrospective cohort study. Crit Care Med 2014; 42 (5) 1157-1167
• 50 Blei AT, Olafsson S, Webster S, Levy R. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet 1993; 341 (8838) 157-158
• 51 Shami VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003; 9 (2) 138-143
• 52 Geerts WH, Bergqvist D, Pineo GF , et al; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl): 381S-453S
• 53 Søgaard KK, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104 (1) 96-101
• 54 Ocak G, Vossen CY, Verduijn M , et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J ThrombHaemost 2013; 11 (1) 116-123
• 55 NICE. Venous thromboembolism: reducing the risk: Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Available at: https://www.nice.org.uk/guidance/cg92 . Published in January 2010. Accessed April 2015.
• 56 Villa E, Cammà C, Marietta M , et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143 (5) 1253-60.e1 , 4
• 57 Gómez Cuervo C, Bisbal Pardo O, Pérez-JacoisteAsín MA. Efficacy and safety of the use of heparin as thromboprophylaxis in patients with liver cirrhosis: a systematic review and meta-analysis. Thromb Res 2013; 132 (4) 414-419
• 58 Northup PG, Sundaram V, Fallon MB , et al; Coagulation in Liver Disease Group. Hypercoagulation and thrombophilia in liver disease. J ThrombHaemost 2008; 6 (1) 2-9
• 59 Agarwal B, Shaw S, Shankar Hari M, Burroughs AK, Davenport A. Continuous renal replacement therapy (CRRT) in patients with liver disease: is circuit life different?. J Hepatol 2009; 51 (3) 504-509
• 60 Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362 (9) 823-832
• 61 Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004; 40 (3) 652-659
• 62 O'Brien J, Triantos C, Burroughs AK. Management of varices in patients with cirrhosis. Nat Rev GastroenterolHepatol 2013; 10 (7) 402-412
• 63 Villanueva C, Colomo A, Bosch A , et al. Transfusion strategies for acute upper gastrointestinal bleeding. [Erratum appears in N Engl J Med. 2013 Jun 13;368(24):2341] N Engl J Med 2013; 368 (1) 11-21
• 64 Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999; 353 (9147) 139-142
• 65 Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005; 54 (4) 556-563
• 66 de Franchis R ; Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53 (4) 762-768
• 67 Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F , et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment PharmacolTher 2011; 34 (5) 509-518
• 68 Weeder PD, Porte RJ, Lisman T. Hemostasis in liver disease: implications of new concepts for perioperative management. Transfus Med Rev 2014; 28 (3) 107-113
• 69 Boks AL, Brommer EJ, Schalm SW, Van Vliet HH. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986; 6 (1) 79-86
• 70 Bosch J, Thabut D, Albillos A , et al; International Study Group on rFVIIa in UGI Hemorrhage. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology 2008; 47 (5) 1604-1614
• 71 Bosch J, Thabut D, Bendtsen F , et al; European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127 (4) 1123-1130
• 72 Vieira da Rocha EC, D'Amico EA, Caldwell SH , et al. A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation. ClinGastroenterolHepatol 2009; 7 (9) 988-993
• 73 Bennett C, Klingenberg SL, Langholz E, Gluud LL. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2014; 11: CD006640
• 74 DeLeve LD, Valla DC, Garcia-Tsao G ; American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49 (5) 1729-1764
• 75 Tait C, Baglin T, Watson H , et al; British Committee for Standards in Haematology. Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol 2012; 159 (1) 28-38